- Oncocyte first to published randomized interventional data to rule-in for biopsy in high-risk patient population
- Study shows that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies
- Early detection of transplant rejection is growing in significance as novel therapeutic treatments show promising early results in antibody mediated rejection.
- Study published in Nephrology Dialysis Transplantation
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (NASDAQ:OCX), a diagnostics technology company, today announced additional favorable data regarding its lead assay VitaGraft, which was published in the journal, Nephrology Dialysis Transplantation.
